150 related articles for article (PubMed ID: 3587117)
1. Intensive chemotherapy including cisplatin with or without etoposide for children with soft-tissue sarcomas.
Crist WM; Raney RB; Ragab A; Heyn R; Wharam M; Webber B; Johnston J; Beltangady M
Med Pediatr Oncol; 1987; 15(2):51-7. PubMed ID: 3587117
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
[TBL] [Abstract][Full Text] [Related]
3. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
Raney RB; Anderson JR; Barr FG; Donaldson SS; Pappo AS; Qualman SJ; Wiener ES; Maurer HM; Crist WM
J Pediatr Hematol Oncol; 2001 May; 23(4):215-20. PubMed ID: 11846299
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
[TBL] [Abstract][Full Text] [Related]
6. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
Ruymann FB; Vietti T; Gehan E; Wiener E; Wharam M; Newton WA; Maurer H
J Pediatr Hematol Oncol; 1995 Nov; 17(4):331-7. PubMed ID: 7583389
[TBL] [Abstract][Full Text] [Related]
8. The Third Intergroup Rhabdomyosarcoma Study.
Crist W; Gehan EA; Ragab AH; Dickman PS; Donaldson SS; Fryer C; Hammond D; Hays DM; Herrmann J; Heyn R
J Clin Oncol; 1995 Mar; 13(3):610-30. PubMed ID: 7884423
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of cisplatin and etoposide in children with advanced soft tissue sarcoma: a report from the Italian Cooperative Rhabdomyosarcoma Group.
Carli M; Perilongo G; di Montezemolo LC; De Bernardi B; Ceci A; Paolucci G; Pianca C; Calculli G; Di Tullio MT; Grotto P
Cancer Treat Rep; 1987 May; 71(5):525-7. PubMed ID: 3567976
[TBL] [Abstract][Full Text] [Related]
10. Preliminary results of alternating combination chemotherapy (CT) and hyperfractionated radiotherapy (HART) in advanced rhabdomyosarcoma (RMS).
Mandell LR; Ghavimi F; Exelby P; Fuks Z
Int J Radiat Oncol Biol Phys; 1988 Jul; 15(1):197-203. PubMed ID: 2455700
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
Edmonson JH; Petersen IA; Shives TC; Mahoney MR; Rock MG; Haddock MG; Sim FH; Maples WJ; O'Connor MI; Gunderson LL; Foo ML; Pritchard DJ; Buckner JC; Stafford SL
Cancer; 2002 Feb; 94(3):786-92. PubMed ID: 11857314
[TBL] [Abstract][Full Text] [Related]
12. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS
Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484
[TBL] [Abstract][Full Text] [Related]
13. [New combination chemotherapy in refractory rhabdomyosarcoma of the prostate: a case report and review of the literature].
Takeuchi T; Komeda H; Oguchi K; Ishihara S; Iwata H; Kanematsu M; Kuriyama M; Ban Y; Tanaka T
Hinyokika Kiyo; 1987 Nov; 33(11):1899-905. PubMed ID: 2451411
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of a rapid etoposide-cisplatin regimen in paediatric soft tissue sarcomas.
Phillips MB; Pinkerton CR
Eur J Cancer; 1992; 28(2-3):399-403. PubMed ID: 1591053
[TBL] [Abstract][Full Text] [Related]
15. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
16. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.
Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ
J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528
[TBL] [Abstract][Full Text] [Related]
17. Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group study.
Pratt CB; Maurer HM; Gieser P; Salzberg A; Rao BN; Parham D; Thomas PR; Marcus RB; Cantor A; Pick T; Green D; Neff J; Jenkins JJ
Med Pediatr Oncol; 1998 Apr; 30(4):201-9. PubMed ID: 9473754
[TBL] [Abstract][Full Text] [Related]
18. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study.
Arndt C; Tefft M; Gehan E; Anderson J; Jenson M; Link M; Donaldson S; Breneman J; Wiener E; Webber B; Maurer H
J Pediatr Hematol Oncol; 1997; 19(2):124-9. PubMed ID: 9149741
[TBL] [Abstract][Full Text] [Related]
19. [A infant case of rhabdomyosarcoma arising from the left iliac region with complete remission for 2 years after combination therapy].
Shimabuku M; Muto Y; Hokama A; Tokumine F; China K; Gushiken T; Sonan S; Hirayama K; Toda T
Gan To Kagaku Ryoho; 1993 Apr; 20(5):657-60. PubMed ID: 8470926
[TBL] [Abstract][Full Text] [Related]
20. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.
Kushner BH; LaQuaglia MP; Bonilla MA; Lindsley K; Rosenfield N; Yeh S; Eddy J; Gerald WL; Heller G; Cheung NK
J Clin Oncol; 1994 Dec; 12(12):2607-13. PubMed ID: 7527454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
